Should Oculis Completing Phase 3 Trials for Topical DME Drug OCS-01 Require Action From OCS Investors? [Yahoo! Finance]
Oculis Publishes Invitation to the Annual General Meeting
Oculis (OCS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema [Yahoo! Finance]
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema